| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | NVP-231 | CTRPv2 | pan-cancer | AAC | 0.02 | 0.5 |
| mRNA | PD-0325901 | gCSI | pan-cancer | AAC | -0.033 | 0.6 |
| mRNA | CH5424802 | GDSC1000 | pan-cancer | AAC | -0.021 | 0.6 |
| mRNA | Platin | CTRPv2 | pan-cancer | AAC | -0.022 | 0.6 |
| mRNA | Compound 1541A | CTRPv2 | pan-cancer | AAC | 0.023 | 0.6 |
| mRNA | MG-132 | CTRPv2 | pan-cancer | AAC | 0.036 | 0.6 |
| mRNA | GSK2636771 | CTRPv2 | pan-cancer | AAC | 0.026 | 0.6 |
| mRNA | selumetinib:navitoclax (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.022 | 0.6 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | 0.032 | 0.6 |
| mRNA | AM-580 | CTRPv2 | pan-cancer | AAC | 0.022 | 0.6 |